Your session is about to expire
← Back to Search
Albumin group for Liver Transplant
N/A
Waitlist Available
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative
Awards & highlights
Study Summary
The purpose of the study is to examine if outcome after liver transplantation is improved by using albumin infusion post-transplantation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ post-op day 7, 15, 30
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-op day 7, 15, 30
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Liver Function Tests
Secondary outcome measures
Calculated creatinine clearance
Functional 6 minutes walking test
Functional hand grip Jamar Dynamometer hand grip test
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Albumin groupExperimental Treatment1 Intervention
Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
Group II: Control GroupActive Control1 Intervention
Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
442 Previous Clinical Trials
159,074 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger